Baxter International (BAX)
Supplies hospital infusion, connected-care, surgical, respiratory, and injectable medicine products.
$23.74
vs last close+0.06 (+0.23%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,599 | 3,885 | 2,490 | 2,694 | 2,699 | 2,753 | 2,625 | 2,810 | 2,835 | 2,974 | 2,701 | 2,960 |
| Cost of revenue | 1,543 | 2,413 | 1,529 | 1,663 | 1,666 | 1,794 | 1,764 | 1,819 | 1,885 | 2,397 | 1,810 | 1,928 |
| Gross profit | 1,056 | 1,472 | 961 | 1,031 | 1,033 | 959 | 861 | 991 | 950 | 577 | 891 | 1,032 |
| 877 | 1,143 | 846 | 852 | 878 | 1,394 | 803 | 800 | 778 | 1,306 | 825 | 815 | |
| Research & development | 133 | 172 | 120 | 130 | 129 | 211 | 140 | 134 | 118 | 126 | 139 | 129 |
| 744 | 977 | 729 | 723 | 754 | 761 | 703 | 718 | 708 | 761 | 728 | 735 | |
| Selling & marketing | 0 | 0 | −266 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 995 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 728 | 735 |
| Other expenses | 0 | −6 | −3 | −1 | −5 | 422 | −40 | −52 | −48 | 419 | −42 | −49 |
| Operating income | 179 | 329 | 115 | 179 | 155 | −435 | 58 | 191 | 172 | −729 | 66 | 217 |
| −115 | −91 | −69 | −62 | −86 | −86 | −61 | −58 | −51 | −27 | −72 | −59 | |
| Interest income | 9 | 44 | 25 | 18 | 14 | 10 | 17 | 14 | 10 | 11 | 12 | 13 |
| Interest expense | 136 | 117 | 103 | 104 | 101 | 100 | 81 | 72 | 68 | 69 | 78 | 77 |
| Other non-operating income | −21 | −26 | −34 | −42 | −15 | −14 | −20 | −14 | −17 | −42 | 6 | −18 |
| Income before tax | 64 | 238 | 46 | 117 | 69 | −521 | −3 | 133 | 121 | −756 | −6 | 158 |
| Income tax expense | 27 | 165 | 40 | 22 | 8 | −33 | −67 | 11 | 172 | 279 | 11 | 23 |
| Net income from continuing operations | 37 | 73 | 6 | 95 | 61 | −488 | 64 | 122 | −51 | −1,035 | −17 | 135 |
| Discontinued operations | 2,474 | 173 | 33 | −406 | 83 | −22 | 62 | −31 | 5 | −93 | 2 | −9 |
| Net income | 2,508 | 245 | 37 | −314 | 140 | −512 | 126 | 91 | −46 | −1,128 | −15 | 126 |
| EPS, basic | $4.95 | $0.48 | $0.07 | −$0.61 | $0.28 | −$1.00 | $0.25 | $0.18 | −$0.09 | −$2.16 | −$0.03 | $0.24 |
| EPS, diluted | $4.93 | $0.48 | $0.07 | −$0.61 | $0.27 | −$1.00 | $0.25 | $0.18 | −$0.09 | −$2.16 | −$0.03 | $0.24 |
| Weighted average shares, basic | 507 | 507 | 508 | 510 | 510 | 510 | 512 | 513 | 514 | 514 | 515 | 517 |
| Weighted average shares, diluted | 507 | 507 | 510 | 510 | 512 | 510 | 514 | 514 | 514 | 514 | 515 | 518 |
| EBITDA | 292 | 679 | 420 | 448 | 424 | −176 | 325 | 462 | 426 | −447 | 297 | 474 |
| Depreciation & amortization | 92 | 324 | 271 | 227 | 254 | 245 | 247 | 257 | 237 | 240 | 237 | 239 |
| EBIT | 200 | 355 | 149 | 221 | 170 | −421 | 78 | 205 | 189 | −687 | 60 | 235 |
